Inflammatory bowel disease: Etiology, pathogenesis and current therapy

Current Pharmaceutical Design

Volumn 20, Issue 7, 2014, Pages 1082-1096

  Ko, Joshua K ^a   Auyeung, Kathy K ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Adhesion molecules; Cytokines; Immunomodulation; Inflammatory bowel disease; Neutrophils; Pharmacotherapy; Reactive oxygen nitrogen metabolites

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; PROBIOTIC AGENT;

DRUG EFFECTS; HUMAN; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASES; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASES; MOLECULAR TARGETED THERAPY; PROBIOTICS;

EID: 84895092508     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990416     Document Type: Review

References (233)

1. Knigge KL. Inflammatory bowel disease. Clin Cornerstone 2002; 4: 49-60.
2. Sung JJ, Hsu RK, Chan FK, Liew CT, Lau JW, Li AK. Crohn's disease in the Chinese population. An experience from Hong Kong. Dis Colon Rectum 1994; 37: 1307-9.
3. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2003; 359: 331-40.
4. Papadakis KA, Targan SR. Current theories on the cause of inflammatory bowel disease. Gastroenterol Clin N Am 1999; 28: 283-96.
5. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clinical Microbiol Rev 2002; 15: 79-94.
6. rd ed. London: Churchill Livingstone 1997; pp. 95-105.
7. Wilks S. Lectures on pathology anatomy. London: Longman 1859.
8. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
9. Lowe AM, Roy PO, B-Poilin M, et al. Epidemiology of Crohn's disease in Quebec, Canada. Inflamm Bowel Dis 2009; 15: 429-35.
10. Loftus EV Jr. Management of extraintestinal manifestations and other complications of inflammatory bowel disease. Curr Gastroenterol Rep 2004; 6(6): 506-13.
11. Binder V. Epidemiology of IBD during the twentieth century: an integrated view. Best Practice Res Clin Gastroenterol 2004; 18(3): 463-79.
12. Thia KT, Loftus EV Jr, Sandborn WJ, Yang S. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008; 103: 3167-82.
13. Su CY, Lichtenstein GR. Recent developments in inflammatory bowel disease. Med Clin N Am 2002; 86: 1497-523.
14. Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut 1988; 29: 990-6.
15. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
16. Satsangi J, Parkes M, Louis E, et al. Contribution of genes of the histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996; 347: 1212-7.
17. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996; 379: 821-3.
18. Rioux JD, Daly MJ, Green T, et al. Absence of linkage between inflammatory bowel disease and selected loci on chromosomes 3,7,12, and 16. Gastroenterology 1998; 115: 1062-5.
19. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996; 14: 199-202.
20. Futami S, Aoyama N, Honsako Y, et al. HLA-DRB1*1502 allele, subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression. Dig Dis Sci 1995; 40: 814-8.
21. Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic marker may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997; 112: 1845-53.
22. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996; 71: 431-6.
23. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000; 118: 279-88.
24. Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000; 118: 274-8.
25. Khor B, Gardet A, Xavier R. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-17.
26. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-34.
27. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011; 140: 1704-12.
28. Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology 2007; 133: 1327-39.
29. Ng SC, Tsoi KK, Kamm MA, et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis 2012; 18(6): 1164-76.
30. Cheon JH. Genetics of inflammatory bowel diseases: a comparison between Western and Eastern perspectives. J Gastroenterol Hepatol 2013 [E-pub ahead of print; accepted on 27 Oct, 2012]
31. Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 2011; 140: 1729-37.
32. Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins: results of a nationwide study. Scand J Gastroenterol 2000; 35: 1075-81.
33. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54.
34. th ed. Philadelphia: WB Saunders 2000; pp.153-78.
35. nd ed. Academic Press: San Diego 1999; pp.1007-24.
36. Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immunol 2001; 69: 2277-85.
37. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998; 115: 1405-13.
38. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54.
39. Cashman KD, Shanahan F. Is nutrition an aetiological factor for inflammatory bowel disease? Eur J Gastroenterolo Hepatol 2003; 15: 607-13.
40. Tragnone A, Valpiani D, Miglio F, et al. Dietary habits as a risk factors for inflammatory bowel disease. Eur J Gastroenterolo Hepatol 1995; 7: 47-51.
41. Reif S, Klein I, Lubin F, Farbstein M, Hallak A, Gilat T. Pre-illness dietary factors in inflammatory bowel disease. Gut 1997; 40: 754-60.
42. Thornton JR, Emmet PM, Heaton KW. Diet and Crohn's disease: characteristics of the preillness diet. BMJ 1979; 2: 762-4.
43. Corrao G, Tragnone A, Caprilli R, et al. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study-Cooperative investigators of the Italian Group for the study of the colon and the rectum (GISC). Int J Epidemiol 1998; 27: 397-404.
44. Geerling BJ, Stockbrugger RW, Brummer RJ. Nutrition and inflammatory bowel disease: an update. Scand J Gastroenterol 1999; 230: 95-105.
45. Stein RB, Lichtensein GR, Rombeau JL. Nutrition and inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 1999; 2: 367-71.
46. Luk HH, Ko JK, Fung HS, Cho CH. Delineation of the protective action of zinc sulfate on ulcerative colitis in rats. Eur J Pharmacol 2002; 443: 197-204.
47. Harries AD, Baird A, Rhodes J. Non-smoking: a feature of ulcerative colitis. Br Med J Clin Res Ed 1982; 284(6317): 706.
48. Koutroubakis I, Manousos ON, Meuwissen SG, Pena AS. Environmental risk factors in inflammatory bowel disease. Hepatogastroenterol 1996; 43(8): 381-93.
49. Benoni C, Nilsson A. Smoking habits in patients with inflammatory bowel disease. A case-control study. Scand J Gastroenterol 1987; 22(9): 1130-6.
50. Samuelsson SM, Ekbom A, Zack M, Helmick CG, Adami HO. Risk factors for extensive ulcerative colitis and ulcerative proctitis: a population based case-control study. Gut 1991; 32(12): 1526-30.
51. Roberts CJ, Diggle R. Non-smoking: a feature of ulcerative colitis. Br Med J 1982; 285: 440.
52. Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126(5): 364-71.
53. Green JT, Thomas GA, Rhodes J, et al. Nicotine enemas for active ulcerative colitis-a pilot study. Aliment Pharmacol Ther 1997; 11(5): 859-63.
54. Guslandi M, Tittobello A. Outcome of ulcerative colitis after treatment with transdermal nicotine. Eur J Gastroenterol Hepatol 1998; 10(6): 513-5.
55. Kennedy LD. Nicotine therapy for ulcerative colitis. Ann Pharmacother 1996; 30: 1022-3.
56. Miller LG, Goldstein G, Murphy M, Ginns LC. Reversible alterations in immunoregulatory T cells in smoking. Analysis by monoclonal antibodies and flow cytometry. Chest 1982; 82(5): 526-529.
57. Srivastava ED, Barton JR, O'Mahony S, et al. Smoking, humoral immunity, and ulcerative colitis. Gut 1991; 32(9): 1016-9.
58. Cope GF, Heatley RV, Kelleher JK. Smoking and colonic mucus in ulcerative colitis. Br Med J Clin Res Ed 1986; 293(6545): 481.
59. Coulie B, Camilleri M, Bharucha AE, Sandborn WJ, Burton D. Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Aliment Pharmacol Ther 2001; 15(5): 653-63.
60. Sher ME, Bank S, Greenberg R, et al. The influence of cigarette smoking on cytokine levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 1999; 5(2): 73-8.
61. Sartor RB. Review article: Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther 1997; 11(Suppl 3): 17-23.
62. Elson CO. Commensal bacteria as targets in Crohn's disease. Gastroenterology 2000; 119: 254-7.
63. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 1997; 186: 1749-56.
64. Mizoguchi A, Mizoguchi E, Chiba C, Bhan AK. Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice. J Exp Med 1996; 184: 707-15.
65. Tabatabai T, Potts JD, Floyd RA. Reactive oxygen speciesmediated inactivation of pyruvate dehydrogenase. Arch Biochem Biophys 1996; 336: 290-6.
66. Simmonds NJ, Rampton DS. Inflammatory bowel disease-a radical view. Gut 1993; 34: 865-8.
67. Cambridge G, Rampton DS, Stevens TR, McCarthy DA, Kamm M, Leaker B. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1992; 33: 668-74.
68. Candeias LP, Patel KB, Stratford MRI, et al. Free hydroxyl radicals are formed on reaction between neutrophil-derived species superoxide anion and hypochlorus acid. FEBS Lett 1993; 333: 151-3.
69. Riddel RH. Pathology of idiopathic inflammatory bowel disease. In: Kirsner JB, Shorter RG (eds). Inflammatory Bowel Disease. Philadelphia: Lea and Febiger 1988; pp. 329-50.
70. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury: role of reactive oxygen metabolites. Dig Dis Sci 1988; 33: 6S-15S.
71. Sedghi S, Fields JZ, Klamut M, et al. Increased production of luminal enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. Gut 1993; 34: 1191-7.
72. Carter I, Wallace JL. Alteration in rat peripheral blood neutrophil function as a consequence of colitis. Dig Dis Sci 1995; 40: 192-7.
73. Morris GP, Beck PL, Herridge MS, Depew WT, Szewezuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96: 795-803.
74. Saiki T. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Kurume Med J 1998; 45: 69-73.
75. Sedghi S, Klamut M, Keshavarzian A. Elevated breath ethane levels in active ulcerative colitis: evidence for excessive lipid peroxidation. Am J Gastroenterol 1994; 89: 2217-21.
76. Keshavarzian A, Morgan G, Sedghi S, Gordon JH, Doria M. Role of reactive oxygen metabolites in experimental colitis. Gut 1990; 31: 786-90.
77. Jung HC, Eckmann L, Yang SK. A distinct array of proinflammatory cytokines in expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest 1995; 95: 55-65.
78. Aggarwal BB, Puri RK. Human cytokines: their role in disease and therapy. In: Aggarwal BB, Puri RK (eds). Blackwell: Boston 1994.
79. Casini-Raggi V, Kam L, Chong YJL, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease: a novel mechanism of chronic intestinal inflammation. J Immunol 1995; 154: 2434.
80. Andus T, Daig R, Lock G, et al. Balance between proand antiinflammatory cytokines in the colonic mucosa in inflammatory bowel diseases (IBD). Gastroenterology 1995; 108: A770 (Abstract).
81. Andus T, Vogl D, Aschenbrenner E, Köllinger M, Schölmerich J, Gross V. IL-1ra genotype 2 is associated with reduced IL-1ra in colonic mucosa. Gastroenterology 1996; 110: A855 (Abstract).
82. Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999; 34: 66-74.
83. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998; 22: 382-9.
84. Ardizzone S, Porro GB. Inflammatory bowel disease: new insights into pathogenesis and treatment J Int Med 2002; 252: 475-96.
85. Sartor RB. Cytokines in interstinal inflammation: pathophysiology and clinical considerations Gastroenterology 1994; 106: 533-9.
86. Dinarello CA. Proinflammatory cytokines. Chest 2000; 118: 503-8.
87. Roussomoustakaki M, Satsangi J, Welch K. Genetic markers may predict disease behaviors in patients with ulcerative colitis Gastroenterology 1997; 112: 1845-53.
88. Reinecker HC, Steffen M, Witthoeft T, et al. Optimizing therapy for inflammatory bowel disease. Am J Gastroenterol 1997; 92: 12S-17S.
89. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000; 117: 1162-72.
90. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin-10 in patients with inflammatory bowel disease. Gastenterology 1995; 108: 1434-44.
91. Raedler A. Enhanced secretion of tumour necrosis factor-alpha, IL6, and IL-1 by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81.
92. Clarke CJP, Hales A, Hunt A. IL-10 mediated suppression of TNF-production is independent of its ability to inhibit NF-B activity. Eur J Immunol 1998; 28: 1719-26.
93. rd millennium: pathogenesis and therapeutic implications? Eur J Gastroenteral Hepatol 1999; 11: 27-32.
94. Litterio JJ, Roberts AB. TGF-: a critical modulator of immune cell function. Clin Immunol Immunopathol 1997; 84: 244-50.
95. Ala A, Dhillon AP, Hodgson HJ. Role of cell adhesion molecules in leukocyte recruitment in the liver and gut. International J Exp Pathol 2002; 84: 1-16.
96. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte migration: the multistep paradigm. Cell 1994; 76: 301-14.
97. Vainer B. Role of cell adhesion molecules in inflammatory bowel diseases. Scand J Gastroenterol 1997; 32: 401-10.
98. Meenan J, Mevissen M, Monajemi H, et al. Mechanisms underlying neutrophil adhesion to apical epithelial membranes. Gut 1996; 38: 201-5.
99. Parkos CA, Colgan SP, Diamond MS, et al. Expression and polarization of intercellular adhesion molecules-1 on human intestinal epithelia: consequences for CD11b/CD18-mediated interactions with neutrophils. Mol Med 1996; 2: 489-505.
100. Colgan SP, Parkos CA, Delp C, Arnaout MA, Madara JL. Neutrophils migration across cultured intestinal epithelial monolayers is modulated by epithelial exposure to IFN-gamma in a highly polarized fashion. J Cell Biol 1993; 120: 785-9.
101. Lidington EA, Moyes DL, McCormack AM, Rose ML. A comparison of primary endothelial cell lines for studies of immune interactions. Transplant Immunol 1999; 7: 239-46.
102. McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton DF. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 1989; 84: 92-9.
103. Geng JG, Bevilacqua MP, Moore KL. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 1990; 343: 757-60.
104. Malizia G, Calabrese A, Cottone M, et al. Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology 1991; 100: 150-9.
105. Schürmann GM, Aber-Bishop AE, Facer P, et al. Altered expression of cell adhesion molecules in uninvolved gut in inflammatory bowel disease. Clin Exp Immunol 1993; 94: 341-7.
106. Nakamura S, Ohtani H, Watanabe Y, et al. In situ expression of the cell adhesion molecules in inflammatory bowel disease: evidence of immunologic activation of vascular endothelial cells. Lab Invest 1993; 69: 77-85.
107. Schürmann GM, Bishop AE, Facer P, et al. Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease. Gut 1995; 36: 411-8.
108. McCafferty DM, Smith CW, Granger DN, Kubes P. Intestinal inflammation in adhesion molecule-deficient mice: an assessment of P-selectin alone and in combination with ICAM-1 or E-selectin. J Leukoc Biol 1999; 66: 67-74.
109. Sans M, Salas A, Soriano A, et al. Differential Role of Selectins in Experimental Colitis. Gastroenterology 2001; 120: 1162-72.
110. Nielson OH, Brynskov J, Vainer B. Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sEselectin, and interleukin-8 in active ulcerative colitis. Dig Dis Sci 1996; 41: 1780-5.
111. Goggins MG, Goh J, O'Connell MA, Weir DG, Kelleher D, Mahmud N. Soluble adhesion molecules in inflammatory bowel disease. Int J Med Sci 2001; 179: 107-11.
112. Ayres RC, Neuberger JM, Shaw J, Joplin R, Adams DH. Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of proinflammatory cytokines. Gut 1993; 34: 1245-9.
113. Vainer B, Nielsen OH. Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecules-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease. Clin Exp Immunol 2000; 121: 242-7.
114. Freedman AS, Munro JM, Rice GE, et al. Adhesion of human B cells to germinal centres in vitro involves VLA-4 and INCAM-110. Science 1990; 249: 1030-3.
115. Koch AE, Burrows JC, Haines KG, et al. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest 1991; 64: 313.
116. Rice GE, Munro JM, Coreless C, Bevilacqua MP. Vascular and nonvascular expression of INCAM-110: a target for mononuclear leukocyte adhesion in normal and inflamed human tissues. Am J Pathol 1991; 138: 385-93.
117. Seron D, Cameron JS, Haskard DO. Expression of VCAM-1 in the normal and diseased kidney. Nephrol Dialysis Transplant 1991; 6: 917-22.
118. Erle DJ, Briskin MJ, Butcher E. Expression and function of the MAdCAM-1 receptor integrin 4 7 on human leukocytes. J Immunol 1994; 153: 517-28.
119. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151: 97-110.
120. Jones SC, Banks RE, Haidar A, et al. Adhesion molecules in inflammatory bowel disease. Gut 1995; 36: 724-30.
121. Berman AE, Kozlova NI. Integrins: structure and functions. Membrane Cell Biol 2000; 13: 207-44.
122. Nielsen OH, Vainer B. Beta 2 integrins inhibit ICAM-1 induced neutrophil locomotion in ulcerative colitis. Gastroenterology 2000; 118(Suppl 12): 1879.
123. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous? Aliment Pharmacol Ther 2002; 16: 1997-2015.
124. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365-76.
125. Kooij A. A re-evaluation of the tissue distribution and physiology of xanthine oxidoreductase. Histochem J 1994; 26: 889-915.
126. Freidl HP, Till GO, Ryan US, Ward PA. Mediator induced activation of xanthine oxidase in endothelial cells. FASEB J 1989; 3: 2512-8.
127. Simmonds NJ, Rampton DS. Inflammatory bowel disease-a radical view. Gut 1993; 34: 865-8.
128. Sturzaker HG, Hawley PR. collagenase activity in rectal and colonic biopsies. Proc R Soc Med 1975; 68: 33.
129. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-4.
130. Cohen AB, Chenoweth DE, Hugli TE. The release of elastase, myeloperoxidase, and lysozme from human alveolar macrophages. Am Rev Respir Dis 1982; 126: 241-7.
131. Tsuruta T, Tani K, Hoshika A, et al. Myeloperoxidase gene expression and regulation by myeloid growth factors in normal and leukemic cells. Leuko Lymphoma 1999; 32: 257-67.
132. Ma TY, Hollander D, Freeman D, et al. Oxygen free radical injury of IEC-18 small intestinal epithelial cell monolayers. Gastroenterology 1991; 100: 1533-43.
133. Lubec G. The hydroxyl radical: from chemistry to human disease. J Invest Med 1996; 44: 324-46.
134. Kehrer JP. The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 2000; 149: 43-50.
135. Candeias LP, Patel KB, Stratford MRI, et al. Free hydroxyl radicals are formed on reaction between neutrophil-derived species superoxide anion and hypochlorus acid. FEBS Lett 1993; 333: 151-3.
136. Tabatabai T, Potts JD, Floyd RA. Reactive oxygen speciesmediated inactivation of pyruvate dehydrogenase. Arch Biochem Biophys 1996; 336: 290-6.
137. Halliwell B. Antioxidants in human health and disease. Ann Rev Nutr 1996; 16: 33-50.
138. Halliwell B. Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Mutat Res 1999; 443: 37-52.
139. nd ed. Oxford: Clarendon Press 1989.
140. Simmonds NJ, Rampton DS. Inflammatory bowel disease-a radical view. Gut 1993; 34: 865-8.
141. Gutteridge JMC. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995; 41: 1819-28.
142. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury: role of reactive oxygen metabolites. Dig Dis Sci 1988; 33: 6S-15S.
143. Barners PJ, Karin M. Nuclear factorB-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
144. Kamata H, Hirata H. Redox regulation of cellular signaling. Cell Signal 1999; 11: 1-14.
145. Gaginella TS, Kachur JF, Tamai H, Keshavarzian A. Reactive oxygen and nitrogen metabolites as mediators of secretory diarrhea. Gastroenterology 1995; 109: 2019-28.
146. Chiarpotto E, Scavazza A, Leonarduzzi G, et al. Oxidative damage and transforming growth factor beta 1 in pretumoral and tumoral lesions of human intestine. Free Rad Biol Med 1997; 22: 889-94.
147. Selley ML. Determination of the lipid peroxidation product 4hydroxy-2-nonenal in clinical samples by gas chromatography-negative-ion chemical ionization mass spectrometry of the Opentafluorobenzyl oxime. J Chromatogr B Biomed Sci Appl 1997; 691: 263-8.
148. Halliwell B. Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Mutat Res 1999; 443: 37-52.
149. Harding JJ, Blakytny R, Ganea E. Glutathione in disease. Biochem Soc Trans 1996; 24: 881-3.
150. Zucker B, Hanusch J, Bauer G. Glutathione depletion in fibroblasts is the basis for apoptosis-induction by endogenous oxygen species. Cell death Diff 1997; 4: 388-95.
151. Xu Y, Jones BE, Neufeld DS, et al. Glutathione modulates rat and mouse hepatocyte sensitivity to tumor necrosis factor toxicity. Gastroenterology 1998; 115: 1229-37.
152. Martensson J, Jain A, Meister A. Glutathione is required for intestinal function. Proc Natl Acad Sci USA 1990; 87: 1715-9.
153. Olson CE. Glutathione modulates toxic oxygen metabolite injury of canine chief cell monolayers in primary culture. Am J Physiol 1988; 254: G49-56.
154. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous? Aliment Pharmacol Ther 2002; 16: 1997-2015.
155. Grisham MB. Role of reactive oxygen metabolites in inflammatory bowel disease. Curr Opin Gastroenterol 1993; 9: 971-80.
156. Lih-Brody L, Powell SR, Collier KP, et al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 1996; 41: 2078-86.
157. Loguercio C, Argenio GD, Cave MD, et al. Direct evidence of oxidative damage in acute and chronic phases of experimental colitis in rats. Dig Dis Sci 1996; 41: 1204-11.
158. Kruidenier L, Kuiper G, Van Duijn W, et al. Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. J Pathol 2003; 201(1): 7-16.
159. Kruidenier L, Kuiper G, Van Duijn W, et al. (2003b) Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Patho 2003; 201(1):17-27.
160. Buffinton GD, Doe WF. Depleted mucosal antioxidant defences in inflammatory bowel disease. Free Radical Biol Med 1995; 19: 911-8.
161. Ramakrishna BS, Varghese R, Jayakumar S, Mathan m, Balasubramanian KA. Circulating antioxidants in ulcerative colitis and their relationship to disease severity and activity. J Gastroenterol Hepatol 1997; 12: 490-4.
162. Sturniolo GC, Mestriner C, Lecis PE, et al. Altered plasma and mucosal concentrations of trace elements and antioxidants in active ulcerative colitis. Scand J Gastroenterol 1988; 33: 644-9.
163. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
164. Moochhala S, Chhatwal VJ, Chan ST, Ngoi SS, Chia YW, Rauff A. Nitric oxide sythase activity and expression in human colorectal cancer. Carcinogenesis 1996; 17: 1171-4.
165. Albina JE. On the expression of nitric oxide synthase by human macrophages. Why no NO? J Leuko Biol 1995; 58: 643-9.
166. Nathan C, Xie QW. Nitric oxide synthase: roles, tolls, and controls. Cell 1994; 78: 915-8.
167. Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol 1996; 271: C1424-37.
168. Grisham MB, Jourd'Heuil D, Wink DA. Nitric oxide. I. Phsiological chemistry of nitric oxide and its metabolites: implications in inflammation. Am J Physiol 1999; 276: G572-5.
169. Kubes P, McCafferty DM. Nitric oxide and intestinal inflammation. Am J Med 2000; 109: 150-8.
170. Lefer AM, Lefer DJ. Nitric oxide. II. Nitric oxide protects in intestinal inflammation. Am J Physiol 1999; 276: G572-5.
171. 2+-independent permeabilization of the inner mitochrondrial membrane by peroxynitrite is mediated by membrane protein thiol cross-linking and lipid peroxidation. Arch Biochem Biophys 1997; 345: 243-50.
172. Bauer ML, Beckman JS, Bridges RJ, et al. Peroxynitrite inhibits sodium uptake in rat colonic membrane vesicles. Biochem Biophys Acta 1992; 1104: 87-94.
173. Greenacre S, Ridger V, Wilsoncroft P, et al. Peroxynitrite: a mediator of increased microvascular permeability? Clin Exp Pharmacol Physiol 1997; 24: 880-2.
174. Roediger WE, Lawson MJ, Nance SH, Radcliffe BC. Detectable colonic nitrite levels in inflammatory bowel disease-mucosal or bacterial malfunction? Digestion 1986; 35: 199-204.
175. Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut 1995; 36: 718-23.
176. Kimura H, Miura S, Shigematsu T, et al. Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease. Dig Dis Sci 1997; 42: 1047-54.
177. Godkin AJ, De Belder AJ, Villa L, et al. Expression of nitric oxide synthase in ulcerative colitis. Eur J Clin Invest 1996; 26: 867-72.
178. Ikeda I, Kasajima T, Ishiyama S, et al. Distribution of inducible nitric oxide synthase in ulcerative colitis. Am J Gastroenterol 1997; 92: 1339-41.
179. Izzo AA, Mascolo N, Capasso F. Nitric oxide as a modulator of intestinal water and electrolyte transport. Dig Dis Sci 1998; 43: 1605-20.
180. Gaginella TS, Kachur JF, Tamai H, Keshavarzian A. Reactive oxygen and nitrogen metabolites as mediators of secretory diarrhea. Gastroenterology 1995; 109: 2019-28.
181. st century. Eng J Surg 1998; S582: 90-8.
182. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated disease: basic and clinical correlates. Ann Intern Med 1993; 119: 1198-1208.
183. Lindmard B. Short and long term steroid side effects: the importance for patients with inflammatory bowel disease. Res Clin Forum 1993; 15: 35-41.
184. Mulder CJJ, Tytgat GNJ. Topical corticosteroids in inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 125-130.
185. Hanauer SB, Robinson M, Pruitt R. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a doseranging study-US Budesonide enema study group Gastroenterology 1998; 115: 525-32.
186. Lofberg R, Danielsson A, Suhr O. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis Gastroenterology 1996; 110: 1713-8.
187. Hanauer SB. Drug Therapy: Inflammatory Bowel Disease. N Engl J Med 1996; 334(13): 841-8.
188. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American college of Gastroenterology, Practice Parameters Committe. Am J Gastroenterol 1997; 92(2): 204-11.
189. Sutherland L, Roth D, Bech P, et al. Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis. Cochrane Database Syst Rev 2000; (2): CD000544
190. Walker A.M., Szneke P, Bianchim LA, et al. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Am J Gastroenterol 1997; 92(5): 816-20.
191. Adler DJ, Korelitz BI. The therapeutic efficacy of 6mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85(6): 717-22.
192. Ardizzone S, Molteni P, Imbesi V, et al. Azathioprine in steroidresistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997; 25(1): 330-3.
193. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305(6844): 20-2.
194. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91: 423-33.
195. Farrell RJ, Ang Y, Kileen P. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000; 47: 514-9.
196. Van Gossum A, Schmit A, Adler M. Shortand long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis: Belgian IBD Group. Acta Gastroenterol Belgium 1997; 60: 197-200.
197. Kornbluth A., Present DH, Lichtiger S, Hanauer S. (1997a) Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol. 92(9): 1424-1428.
198. Quan VA, Saunders BP, Hicks BH, Sladen GE. Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia. BMJ 1997; 314: 363-4.
199. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94(6): 1587-92.
200. Stack WA, Long RG, Hawkey CJ. Shortand long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998; 12(10): 973-8.
201. Stein R.B., Hanauer SB. (1998) Life-threatening complications of IBD: how to handle fulminant colitis and toxic megacolon. J Crit Illness 13: 518.
202. Sandborn W., McLeod R, Jewell D. (2000) Pharmacotherapy for inducing and maintaining remission in pouchitis. Cochrane Database Syst Rev 2000; (2):CD001176.
203. Turunen UM, Farkkila MA, Hakala K. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study Gastroenterology 1998; 115: 1072-8.
204. Giouchette P, Rizzello F, Ferrieri A. Riflaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial Dig Dis Sci 1999; 44: 1220-1.
205. Kennedy RJ, Kirk SJ, Gardiner KR. Probiotics in IBD. Gut 2001; 49(6): 873.
206. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis 2000; 6(2): 107-15.
207. Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 1996; 183(6): 2605-16.
208. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Doubleblind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11(5): 853-8.
209. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354(9179): 635-9.
210. Armstrong AM, Gardiner KR, Kirk SJ. Tumour necrosis factor and inflammatory bowel disease Br J Surg 1997; 84: 1051-8.
211. Present DH. Review article: the efficacy of infliximab in Crohn's disease-healing of fistulae. Aliment Pharmacol Ther 1999; 13(Suppl 4): 23-8.
212. Su CY, Lichtenstein GR. Recent developments in inflammatory bowel disease. Med Clin N Am 2002; 86: 1497-523.
213. Chey WY, Hussain A, Ryan C. Infliximab for refractory UC. Am J Gastroenterol 2001; 96: 2373-81.
214. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000; 118: S68-82.
215. Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010; 45: 571-83.
216. Barbara G, Xing Z, Hogaboam CM, Gauldie J, Collins SM. Interleukin 10 gene transfer prevents experimental colitis in rats. Gut 2000; 46: 344-9.
217. Lindsay J, Van Montfrans C, Brennan F, et al. IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther 2002; 9: 1715-21.
218. Lindsay JO, Ciesielski CJ, Scheinin T, Hodgson HJ, Brennan FM. The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10. J Immunol 2001; 166: 7625-33.
219. Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol 1992; 87: 432-7.
220. Stenson W, Cort D, Rodgers J. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 1992; 116: 609-14.
221. Dichi I, Frenhane P, Dichi JB. Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis. Nutrition 2000; 16: 87-90.
222. Breuer RI, Soergel KH, Lashner BA. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomized, placebo controlled trial. Gut 1997; 40: 485-91.
223. Talbot RW, Heppell J, Dozois RR, Beart RW Jr. Vascular complication of inflammatory bowel disease. Mayo Clin Proc 1986; 61: 140-45.
224. Korzenik JR. IBD: a vascular disorder? the case for heparin therapy. Inflamm Bowel Dis 1997; 3: 87-92.
225. Korzenik JR, Hsu A, Robert ME. Effect of heparin on dextran sulfate sodium-induced colitis. Dig Dis Sci 1998; 43(8): 1800-5.
226. Rubin DT, Hanauer SB. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12(8): 855-62.
227. Guo X, Wang WP, Ko JKS, Cho CH. Involvement of neutrophils and free radicals in the potentiating effects of passive cigarette smoking on inflammatory bowel disease in rats. Gastroenterology 1999; 117: 884-92.
228. Ko JKS, Sham NF, Guo X, Cho CH. Beneficial intervention of experimental colitis by passive cigarette smoking through the modulation of cytokines in rats. J Invest Med 2001; 49: 21-9.
229. Chow JY, Ma L, Zhu M, Cho CH. The potentiating actions of cigarette smoking on ethanol-induced gastric mucosal damage in rats. Gastroenterology 1997; 113(4): 1188-97.
230. Ko JKS, Cho CH. The diverse actions of nicotine and different extracted fractions from tobacco smoke against hapten-induced colitis in rats. Toxicol Sci 2005; 87(1): 285-95.
231. Ko JKS, Lam FYL, Cheung APL. Amelioration of experimental colitis by Astragalus membranaceus through anti-oxidation and inhibition of adhesion molecule synthesis. World J Gastroenterol 2005; 11(37): 5787-94.
232. Ko JKS, Chik CWS. The protective action of radix Astragalus membranaceus against hapten-induced colitis through modulation of cytokines. Cytokine 2009; 47: 85-90.
233. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Practice Res Clin Gastroenterol 2004; 18(3): 481-96.